Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0524A added to intensive LDL-C lowering therapy for carotid intima-media thickness in heterozygous familial hypercholesterolemia
2006-001913-13Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in familial hypercholesterolemia (FH) comparing MK-0524A plus intensive LDL-C lowering therapy with Placebo plus intensive LDL-C lowering therapy (2 arms). Started Oct 2006; status: terminated.
02
Drugs
laropiprant + niacin
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on 2006-001913-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001913-13.